XG005

Xgene Pharmaceutical Group · Phase 2 active Small molecule

At a glance

Generic name	XG005
Sponsor	Xgene Pharmaceutical Group
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

XG005 for Pain Control in Subjects Undergoing Bunionectomy (PHASE2, PHASE3)
Pharmacokinetics Study of XG005 Capsule (PHASE1)
Phase 1 Pharmacokinetics, Safety, and Tolerability Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XG005 CI brief — competitive landscape report
XG005 updates RSS · CI watch RSS
Xgene Pharmaceutical Group portfolio CI